Literature DB >> 21121779

Evaluating a newly developed pharmacogenetic array: screening in a Spanish population.

Berta Almoguera1, Rosa Riveiro-Alvarez, Belen Gomez-Dominguez, Rosario Lopez-Rodriguez, Pedro Dorado, Concepción Vaquero-Lorenzo, Rafael Dal-Ré, Jose Fernandez-Piqueras, Adrián Llerena, Francisco Abad-Santos, Carmen Ayuso.   

Abstract

AIMS: How genes affect the response in a patient to a given medication is still poorly understood; the validation of biomarkers and technologies need to be performed. This study aims to determine the analytical characteristics of PHARMAChip(®), a newly developed pharmacogenetic array, and the Spanish population allelic and genotypic frequencies of the genetic variants included in this chip. MATERIALS &
METHODS: The analytical characteristics of PHARMAChip assessed were sensitivity and specificity (for CYP2D6 and SLC6A4), accuracy (for SLC6A4) and genotyping rate: frequencies of the 90 pharmacogenetic variants of 36 genes were included in PHARMAChip. These were compared in 449 Spanish subjects with data reported in Caucasians. RESULTS &
CONCLUSION: Sensitivity and specificity ranged from 96-100%, accuracy was 94.8% and genotyping success rate was 99.6%. PHARMAChip is an accurate, rapid and updatable tool, which may be especially useful for cytochrome P450 testing. The allelic and genotypic frequencies found in the Spanish subjects reinforce the need for establishing possible intraethnic differences among populations prior to performing this kind of study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21121779     DOI: 10.2217/pgs.10.131

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  3 in total

1.  A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events.

Authors:  M E Moretti; D F Lato; H Berger; G Koren; S Ito; W J Ungar
Journal:  Pharmacogenomics J       Date:  2017-07-11       Impact factor: 3.550

2.  Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.

Authors:  B Almoguera; R Riveiro-Alvarez; J Lopez-Castroman; P Dorado; C Vaquero-Lorenzo; J Fernandez-Piqueras; A Llerena; F Abad-Santos; E Baca-García; R Dal-Ré; C Ayuso
Journal:  Pharmacogenomics J       Date:  2012-01-03       Impact factor: 3.550

3.  The rs1142345 in TPMT Affects the Therapeutic Effect of Traditional Hypoglycemic Herbs in Prediabetes.

Authors:  Xi Li; Feng-Mei Lian; Dong Guo; Lan Fan; Jie Tang; Jing-Bo Peng; Hong-Wen Deng; Zhao-Qian Liu; Xin-Hua Xiao; Yan-Rong Wang; Ke-Yi Qu; Sheng Deng; Qi Zhong; Yi-Ling Sha; Yan Zhu; Yu-Jing Bai; Xin-Yan Chen; Qiang Zhou; Hong-Hao Zhou; Xiao-Lin Tong; Wei Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-29       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.